ClinicalTrials.gg

Program

setidegrasib

Also written as “Setidegrasib” and “14C-labeled ASP3082”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Neoplasms, led by Astellas Pharma.

Furthest: phase 3, since Feb 9, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma43 open or runningphase 3since Feb 9, 2026May 16, 2022Dec 31, 2028phase 1 · NCT05382559

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05382559 · 681 planned · United States, China, France and more
  2. Feb 9, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07409272 · 614 planned · United States, Brazil, China and more
  3. Apr 27, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07566052 · 356 planned · United States, China, Japan
  4. Aug 16, 2026Phase 1 study in Healthy VolunteerNCT07773129 · 8 enrolled · United States

Ahead

  1. Dec 31, 2028Primary completion: phase 1 study in NeoplasmsNCT05382559
  2. Aug 31, 2029Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07409272
  3. Jun 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07566052

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07773129Healthy Volunteer · United States1CompletedOct 20, 20268
NCT07566052Carcinoma, Non-Small-Cell Lung · United States, China, Japan3RecruitingJun 30, 2030356
NCT07409272Pancreatic Neoplasms · United States, Brazil, China and more3RecruitingAug 31, 2029614
NCT05382559Neoplasms · United States, China, France and more1RecruitingDec 31, 2028681

How it is read

Names in the registry

  • “Setidegrasib”, 3 entries
  • “14C-labeled ASP3082”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.